Bioventus (BVS) AI Stock Analysis

• Market Cap: $624.86M
• Dividend Yield: N/A
• Average Volume (3M): 358.37K
• Price to Earnings (P/E): 66.8
• Beta (1Y): 0.87
• Revenue Growth: 1.58%
• EPS Growth: N/A
• Country: US
• Employees: 930
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.15
• Shares Outstanding: 66,976,480
• 10 Day Avg. Volume: 292,657
• 30 Day Avg. Volume: 358,372
• PEG Ratio: 0.26
• Price to Book (P/B): 4.64
• Price to Sales (P/S): 1.20
• P/FCF Ratio: 18.16
• Enterprise Value/Market Cap: 1.28
• Enterprise Value/Revenue: 1.42
• Enterprise Value/Gross Profit: 2.10
• Enterprise Value/Ebitda: 8.90
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.54
• Revenue Forecast (FY): $566.83M

• Rating: 64 Neutral
• Price Target: $7.00 ▲(0.00% Upside)

Bioventus's overall stock score reflects a strong earnings call performance and solid financial improvements, particularly in cash flow and leverage reduction. However, the high P/E ratio and bearish technical indicators weigh down the score. The company's strategic growth initiatives and operational efficiencies are promising, but valuation concerns and technical weaknesses present risks.

Positive Factors

Debt Reduction

Reducing debt enhances financial stability and reduces interest expenses, allowing more resources for growth initiatives and improving creditworthiness.

Organic Revenue Growth

Organic growth indicates strong demand for core products and services, reflecting effective market strategies and potential for sustained revenue expansion.

Cash Flow Generation

Strong cash flow generation supports reinvestment in business operations, reduces reliance on external financing, and enhances financial flexibility.

Negative Factors

Revenue Growth Decline

Declining revenue growth can signal market saturation or competitive pressures, potentially impacting long-term profitability and market share.

Operational Efficiency

Low operational efficiency may limit profitability improvements and indicate challenges in cost management, affecting overall financial performance.

Impact of Divestiture

Divestitures can disrupt revenue streams and require strategic realignment, potentially impacting growth and operational focus in the near term.

Bioventus Business Overview & Revenue Model

Company Description

Bioventus (BVS) is a global leader in the development and commercialization of innovative therapies for musculoskeletal health. The company operates primarily in the orthopedic and pain management sectors, focusing on solutions that enhance healing and improve patient outcomes. Bioventus' core products include its proprietary ultrasound therapy systems, biologic products for joint health, and a range of other advanced medical devices aimed at treating conditions related to bone and soft tissue.

How the Company Makes Money

Bioventus generates revenue through multiple streams, primarily from the sale of its medical devices, biologic products, and therapeutic solutions. The company has a strong focus on the orthopedic market, where it markets its ultrasound devices and other technologies to hospitals, clinics, and outpatient facilities. Significant partnerships with healthcare providers and distributors enhance its market reach and facilitate sales. Additionally, Bioventus may also derive income from research collaborations, licensing agreements, and product development partnerships, which further diversify its revenue sources. The company's commitment to innovation and its pipeline of new products are crucial factors contributing to its earnings potential.

Bioventus Financial Statement Overview

Summary

Bioventus demonstrates a solid financial position with notable improvements in leverage and cash flow generation. While revenue growth has slowed, profitability metrics such as net profit margin and return on equity have improved. The company has effectively reduced its debt burden, enhancing financial stability. However, operational efficiency as indicated by EBIT and EBITDA margins could be further optimized to strengthen overall profitability.

Income Statement

Bioventus shows a mixed performance in its income statement. The TTM data indicates a slight decline in revenue growth at -5.5%, but the company has managed to maintain a positive net profit margin of 1.39%. The gross profit margin remains strong at 67.76%, indicating efficient cost management. However, the EBIT and EBITDA margins are relatively low at 5.52% and 13.98%, respectively, suggesting room for improvement in operational efficiency.

Balance Sheet

The balance sheet reflects a significant improvement in leverage, with the debt-to-equity ratio decreasing to 0.068 in the TTM period from over 2.4 in the previous year. This indicates a stronger equity position and reduced financial risk. The return on equity has improved to 5.02%, showing better profitability relative to shareholders' equity. However, the equity ratio is not explicitly provided, which limits a full assessment of asset financing.

Cash Flow

Cash flow analysis reveals a robust free cash flow growth of 56.82% in the TTM period, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.35, suggesting that operating activities are generating sufficient cash relative to net income. The free cash flow to net income ratio is high at 0.95, reflecting efficient conversion of earnings into cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	563.83M	573.28M	512.35M	512.12M	430.90M	321.16M
Gross Profit	380.63M	388.23M	328.19M	331.08M	302.71M	233.52M
EBITDA	89.70M	39.22M	-23.07M	-121.61M	45.48M	54.31M
Net Income	7.82M	-33.54M	-156.23M	-158.70M	19.38M	16.41M
Balance Sheet
Total Assets	701.59M	727.96M	810.91M	1.37B	1.23B	494.47M
Cash, Cash Equivalents and Short-Term Investments	42.16M	41.58M	36.96M	30.19M	43.93M	86.84M
Total Debt	322.58M	335.63M	394.85M	418.07M	357.68M	188.38M
Total Liabilities	494.34M	542.35M	589.79M	960.43M	692.07M	350.31M
Stockholders Equity	166.10M	147.94M	173.59M	325.24M	458.92M	142.24M
Cash Flow
Free Cash Flow	53.47M	37.79M	7.98M	-15.02M	2.10M	51.13M
Operating Cash Flow	56.03M	38.80M	15.34M	-13.54M	22.99M	71.80M
Investing Cash Flow	21.44M	22.96M	15.81M	-116.44M	-283.76M	-20.50M
Financing Cash Flow	-76.55M	-54.58M	-26.65M	62.08M	273.37M	-29.57M

Bioventus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BVS, the sentiment is Positive. The current price of 7 is below the 20-day moving average (MA) of 7.36, below the 50-day MA of 7.15, and below the 200-day MA of 7.30, indicating a bullish trend. The MACD of 0.08 indicates Positive momentum. The RSI at 54.44 is Neutral, neither overbought nor oversold. The STOCH value of 71.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BVS.

Bioventus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVS	64 Neutral	$624.86M	66.79	4.97%	―	1.58%	―
SIBN	58 Neutral	$806.64M	-36.02	-12.91%	―	23.27%	43.90%
OFIX	55 Neutral	$613.40M	-5.17	-24.60%	―	4.31%	3.26%
KIDS	52 Neutral	$441.36M	-9.20	-12.67%	―	19.90%	-57.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VREX	50 Neutral	$488.31M	-6.83	-13.95%	―	4.14%	-45.29%
ZIMV	48 Neutral	―	―	-4.76%	―	-19.52%	94.65%

Bioventus Corporate Events

Bioventus Appoints Ajay Dhankhar as New Director

On November 14, 2025, Bioventus Inc. appointed Ajay Dhankhar, PhD, as a Class II director, effective immediately, with his term ending at the 2026 annual stockholders meeting. Dr. Dhankhar, who has extensive experience in corporate development and strategy within the healthcare sector, is the second designee of the S+N Stockholders to the Board, alongside Philip G. Cowdy. His appointment aligns with the Stockholders Agreement, which allows Smith & Nephew affiliates to designate directors based on their shareholding. Dr. Dhankhar will not receive compensation from the company for his role.